Alhemo
Payments companies reported to CMS as associated with Alhemo. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Alhemo, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Alhemo
These are the largest totals companies reported as associated with Alhemo. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Richard Lemons | Salt Lake City, UT | Pediatric Hematology-Oncology | $54,166.33 |
| Shveta Gupta | Orlando, FL | Pediatric Hematology-Oncology | $38,988.53 |
| Paulette Bryant | Charlotte, NC | Pediatric Hematology-Oncology | $37,971.55 |
| Jennifer Domm | Nashville, TN | Pediatric Hematology-Oncology | $33,516.38 |
| Vivek Sharma | Louisville, KY | Hematology & Oncology | $25,580.94 |
| Amy Shapiro | Indianapolis, IN | Pediatric Hematology-Oncology | $21,786.23 |
| Doris Quon | Los Angeles, CA | Hematology (Internal Medicine) | $20,157.10 |
| Akshat Jain | Redlands, CA | Pediatric Hematology-Oncology | $17,277.27 |
| Guy Young | Bozeman, MT | Pediatric Hematology-Oncology | $15,200.55 |
| Kim Schafer | Sacramento, CA | Family | $9,903.05 |
Prescribed Alhemo?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.